Myeloproliferative neoplasms (MPNs) are chronic blood cancers that arise due to a defect of the myeloid stem cells in the bone marrow which causes the production of too many abnormal blood cells that do not function properly.
Normal blood stem cells in the bone marrow develop in time into mature blood cells that include:
- Red blood cells: perform tissue oxygenation
- White blood cells: protect against infection and disease
- Platelets: facilitate clotting of blood
MPNs include three main disorders characterised by different excesses of blood cells in the blood and bone marrow:
- Polycythaemia vera (PV): Excess of red blood cells, but occasionally platelets and white blood cells
- Essential thrombocythaemia (ET): Excess of platelets
- Myelofibrosis (MF): Excess of scar tissue (fibrosis) formed in the bone marrow that prevents the production of normal blood cells. MF can occur on its own (primary MF), or following PV or ET (secondary MF).
What you will learn in this module?
- Epidemiology, clinical features and diagnosis of the myeloproliferative neoplasms (MPNs)
- Tests used to diagnose MPNs and monitor its treatment
- Goals of treatment for MPNs
- Treatments for MPNs
- Role of the Clinical Nurse Specialist in managing MPNs
A self-assessment test is included so you can assess your knowledge after the module.
Time to complete this course: 2 hours
Date of publication: February 2021
Review date: February 2024
To assist you with the completion of this course, we’ve put all the course materials into this PDF booklet that can be downloaded.
Course Content
Ratings and Reviews
4.0
Avg. Rating
1 Ratings
5
0
4
1
3
0
2
0
1
0
What's your experience? We'd love to know!
Login to Review
What's your experience? We'd love to know!
Login to Review
I have really enjoyed doing the course, and it is very good as an induction. I would like more in-depth information about treatment, side effects and how to manage this. Also, managing some of the special situation (pregnancy, surgery, thrombosis, haemorrhage) Overall, very good start up.